PUBLISHED ASSESSMENT

Influenza Antiviral Medications: Summary for Clinicians | Influenza (Flu) | CDC

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

The guidance is extensively sourced and accurately distinguishes strong outpatient evidence from lower-certainty hospitalized-patient evidence. It addresses counterevidence, off-label use, adverse effects, resistance, and important population-specific limitations. Transparency is substantial but lacks a documented evidence-review method and reviewer disclosures. One material update issue requires correction: FDA labeling lists baloxavir oral-suspension formulations despite the page stating that suspension is unavailable.

Evidence support

Strong (82/100)

Core indications, age limits, dosing, contraindications, and interactions align with FDA records.
Treatment-efficacy claims cite randomized trials, meta-analyses, and observational evidence.
Hospitalized-patient benefits are appropriately described as observational and uncertain.
The claim that baloxavir suspension is unavailable conflicts with FDA labeling showing marketed suspension formulations.

Balance & context

Strong (90/100)

Clearly distinguishes outpatient trial evidence from lower-certainty hospitalized-patient evidence.
Reports studies finding no mortality reduction alongside favorable observational findings.
Identifies data gaps involving pregnancy, immunocompromised patients, severe disease, resistance, and treatment after 48 hours.
Separates FDA-approved indications from CDC recommendations and expert-opinion uses.

Transparency

Substantial (77/100)

Provides institutional authorship, publication date, extensive attribution, direct study links, tables, and explicit uncertainty statements.
Identifies off-label recommendations and evidence types.
No systematic literature-search method, evidence-grading framework, individual reviewers, or conflict disclosures are presented.

Confidence and coverage

Confidence in this analysis: High confidence

Evidence coverage: Substantial coverage

Not every cited study or dosing detail was independently reviewed.
Formulation availability and antiviral susceptibility are time-sensitive.

Central clinical and regulatory claims were checked against FDA records, surveillance data, and systematic reviews.
The supplied text includes extensive citations and qualification of uncertainty.

Sources considered

FDA: Influenza (Flu) Antiviral Drugs and Related Information — Confirms the four recommended antivirals and non-recommendation of adamantanes due to resistance.
FDA XOFLUZA Prescribing Information, 2026 — Lists oral-suspension packets and bottles, conflicting with the page's availability statement; otherwise supports indications, dosing, and interactions.
FDA RAPIVAB Prescribing Information, 2024 — Supports peramivir age, dosing, renal adjustment, and hospitalized-patient evidence limitations.
Antivirals for Treatment of Severe Influenza: Systematic Review and Network Meta-analysis — Finds very-low-certainty mortality evidence for neuraminidase inhibitors in severe influenza.
Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza — Supports the page's statement that outpatient randomized trials did not demonstrate reduced hospitalization.
CDC FluView: Antiviral Susceptibility, 2025–2026 Season — Supports the claim that reduced antiviral susceptibility was very uncommon in tested circulating viruses.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-13 (current)	82	90	77